This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hansel, D. E. Articles by Maitra, A. Search for Related Content PubMed PubMed Citation Articles by Hansel, D. E. Articles by Maitra, A.

Met Proto-Oncogene and Insulin-Like Growth Factor Binding Protein 3 Overexpression Correlates with Metastatic Ability in Well-Differentiated Pancreatic Endocrine Neoplasms

Departments of ¹ Pathology, ² Surgery, and ³ Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, and ⁴ Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas

Pancreatic endocrine neoplasms are neoplastic proliferations of islet cells or islet cell precursors and are capable of secreting a variety of synthetic products, including insulin, glucagon, gastrin, and vasoactive intestinal peptide. The biological behavior of pancreatic endocrine neoplasms is often unpredictable, and there are few reliable histopathologic criteria reliably correlating with metastatic ability. We have used the Affymetrix U133 GeneChip set (HG_U133 A and B; Affymetrix; Santa Clara, CA) representing 33,000 characterized transcripts to examine global gene expression profiles from well-differentiated nonmetastatic (n = 5) and metastatic (n = 7) pancreatic endocrine neoplasms to determine molecular markers that predict disease progression. Microarray hybridization data were normalized using the GeneLogic GeneExpress Software System to identify differentially up- and down-regulated genes in metastatic versus nonmetastatic pancreatic endocrine neoplasms. Using a 3-fold change in gene expression as a threshold, we have identified 65 overexpressed and 57 underexpressed genes in metastatic pancreatic endocrine neoplasms as compared with nonmetastatic pancreatic endocrine neoplasms. Several classes of genes, including growth factors and growth factor-related molecules (IGFBP1, IGFBP3, and MET), developmental factors (TBX3 and MEIS2), cytoskeletal factors (ß 1 tubulin and ACTN2), cholesterol homeostasis mediators (LRP5, SLC27A2, and RXRG), intracellular signaling pathway mediators (DYRK1A, PKIB, and AK2), methyltransferases (MGMT and GAMT), and DNA repair and regulatory molecules (CHEK1 and ZNF198), were identified as differentially over- or underexpressed via this method. Immunohistochemical validation of microarray data were performed for two overexpressed genes, namely, the met proto-oncogene (MET) and insulin-like growth factor binding protein 3 (IGFBP3) with tissue microarrays of nonmetastatic (n = 24) and metastatic (n = 15) pancreatic endocrine neoplasms. Increased expression of IGFBP3 was confirmed in metastatic versus nonmetastatic pancreatic endocrine neoplasms (12 of 15, 80% versus 10 of 24, 42%), as well as in lymph node (6 of 7, 86%) and liver (9 of 9, 100%) metastases. Similarly, overexpression of MET was confirmed in metastatic versus nonmetastatic pancreatic endocrine neoplasms (5 of 15, 33% versus 4 of 24, 17%), as well as in lymph node metastases (4 of 7, 57%) and liver metastases (5 of 9, 56%). The majority of genes that demonstrated altered expression has not been previously identified as differentially expressed in metastatic pancreatic endocrine neoplasm lesions and may therefore represent newly identified molecules in the progression of these lesions.

This article has been cited by other articles:

				C. Roesli, B. Borgia, C. Schliemann, M. Gunthert, H. Wunderli-Allenspach, R. Giavazzi, and D. Neri Comparative Analysis of the Membrane Proteome of Closely Related Metastatic and Nonmetastatic Tumor Cells Cancer Res., July 1, 2009; 69(13): 5406 - 5414. [Abstract] [Full Text] [PDF]

				T. R Halfdanarson, J. Rubin, M. B Farnell, C. S Grant, and G. M Petersen Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors Endocr. Relat. Cancer, June 1, 2008; 15(2): 409 - 427. [Abstract] [Full Text] [PDF]

				E.-M. Duerr, Y. Mizukami, A. Ng, R. J Xavier, H. Kikuchi, V. Deshpande, A. L Warshaw, J. Glickman, M. H Kulke, and D. C Chung Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumors through DNA microarray analysis Endocr. Relat. Cancer, March 1, 2008; 15(1): 243 - 256. [Abstract] [Full Text] [PDF]

				A. Abrahams, S. Mowla, M. I. Parker, C. R. Goding, and S. Prince UV-mediated Regulation of the Anti-senescence Factor Tbx2 J. Biol. Chem., January 25, 2008; 283(4): 2223 - 2230. [Abstract] [Full Text] [PDF]

				S. V. de Sa, M. L. Correa-Giannella, M. C. Machado, K. Krogh, M. Q. de Almeida, M. A. Albergaria Pereira, S. A. Coelho Siqueira, R. A. Patzina, F. S. Ibuki, M. C. Sogayar, et al. Serpin Peptidase Inhibitor Clade A Member 1 as a Potential Marker for Malignancy in Insulinomas Clin. Cancer Res., September 15, 2007; 13(18): 5322 - 5330. [Abstract] [Full Text] [PDF]

				A. Di Florio, G. Capurso, M. Milione, F. Panzuto, R. Geremia, G. D. Fave, and C. Sette Src family kinase activity regulates adhesion, spreading and migration of pancreatic endocrine tumour cells Endocr. Relat. Cancer, March 1, 2007; 14(1): 111 - 124. [Abstract] [Full Text] [PDF]

				S Fontaniere, J Tost, A Wierinckx, J Lachuer, J Lu, N Hussein, F Busato, I Gut, Z-Q Wang, and C-X Zhang Gene expression profiling in insulinomas of Men1 {beta}-cell mutant mice reveals early genetic and epigenetic events involved in pancreatic {beta}-cell tumorigenesis Endocr. Relat. Cancer, December 1, 2006; 13(4): 1223 - 1236. [Abstract] [Full Text] [PDF]

				Y. Xi, G. Nakajima, T. Hamil, O. Fodstad, A. Riker, and J. Ju Association of insulin-like growth factor binding protein-3 expression with melanoma progression Mol. Cancer Ther., December 1, 2006; 5(12): 3078 - 3084. [Abstract] [Full Text] [PDF]

				C. Roldo, E. Missiaglia, J. P. Hagan, M. Falconi, P. Capelli, S. Bersani, G. A. Calin, S. Volinia, C.-G. Liu, A. Scarpa, et al. MicroRNA Expression Abnormalities in Pancreatic Endocrine and Acinar Tumors Are Associated With Distinctive Pathologic Features and Clinical Behavior J. Clin. Oncol., October 10, 2006; 24(29): 4677 - 4684. [Abstract] [Full Text] [PDF]

				G Capurso, S Lattimore, T Crnogorac-Jurcevic, F Panzuto, M Milione, V Bhakta, N Campanini, S M Swift, C Bordi, G D. Fave, et al. Gene expression profiles of progressive pancreatic endocrine tumours and their liver metastases reveal potential novel markers and therapeutic targets. Endocr. Relat. Cancer, June 1, 2006; 13(2): 541 - 558. [Abstract] [Full Text] [PDF]